Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 11/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 11/20 | 0.51 |
| ▸ | GRIA3 | P42263 | 11/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 11/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 5/20 | 0.48 |
| ▸ | GRIK4 | Q16099 | 5/20 | 0.48 |
| ▸ | GRIK5 | Q16478 | 5/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fanapanel SCHEMBL29352240 | 1.00 | GRIA1 (0.51) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Fanapanel SCHEMBL30546194 | 0.99 | GRIA1 (0.50) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| Fanapanel SCHEMBL25432377 | 0.99 | GRIA1 (0.50) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8107335 | 0.90 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8122798 | 0.90 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8340446 | 0.87 | GRIA1 (0.50) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL7088166 | 0.86 | GRIA1 (0.47) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL2037840 | 0.86 | GRIA1 (0.49) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8341491 | 0.85 | GRIA1 (0.43) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL7885810 | 0.84 | GRIA1 (0.48) | GRIA1GRIA2GRIA3GRIA4GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2255798-B1 | FTY720 for use in the treatment of optic neuritis | NOVARTIS AG (CH) | 2014-12-24 | — | — | EP | claimed |
| EP-1586321-B1 | New use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2008-12-10 | — | — | EP | claimed |
| US-7247610-B2 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI | 2007-07-24 | — | — | US | claimed |
| EP-1586321-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20050054619-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | claimed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| US-5955461-A | Quinoxalinedione derivatives, their production and use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | claimed |
| WO-1999010355-A1 | METHOD FOR PRODUCING PHOSPHONIC ACID DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-04 | — | — | WO | claimed |
| US-5750525-A | Quinoxalinedione derivatives, their production and use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250352607-A1 | GLATIRAMER DEPOT SYSTEMS FOR TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS | MAPI PHARMA LTD. (IL) | 2025-11-20 | — | — | US | disclosed |
| US-12419895-B1 | Methods for treating subjects with Prader-Willi syndrome | ESSENTIALIS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250288593-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME | SOLENO THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-1002796-A2 | Novel quinoxalindione derivatives, their production and use in medicaments | Schering Aktiengesellschaft (DE) | 2000-05-24 | — | — | EP | disclosed |
| US-5955461-A | Quinoxalinedione derivatives, their production and use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | disclosed |
| US-5750525-A | Quinoxalinedione derivatives, their production and use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | disclosed |
| EP-0696288-A1 | QUINOXALINDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994025469-A1 | QUINOXALINDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419895-B1 | Methods for treating subjects with Prader-Willi syndrome | KCNJ1, KCNJ11, KCNN1 | GRIA1 1194/4885GRIA2 1120/4885GRIA3 1332/4885 |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | GRIA1 1312/4885GRIA2 1365/4885GRIA3 1422/4885 |
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | GRIA1 20/4885GRIA2 21/4885GRIA3 18/4885 |
| US-20250288593-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME | KCNJ1, KCNJ11, KCNN1 | GRIA1 1194/4885GRIA2 1120/4885GRIA3 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.